The global autoinjector devices market is on track to reach USD 3.02 billion by 2030, up from USD 1.40 billion in 2024, reflecting a robust CAGR of 13.6%. Alongside this, the autoinjector finished formulations market is set to grow from USD 67.30 billion in 2024 to USD 134.27 billion by 2030, marking a CAGR of 12.2%.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724
Key Drivers of Growth
The growth of the autoinjector market is largely driven by several factors:
- Technological Advancements – A growing launch of advanced autoinjector devices is boosting the market’s expansion, with innovations making self-injections easier, faster, and more accurate.
- Regulatory Approvals – Increasing regulatory approvals for finished formulations in autoinjector formats are opening up new opportunities in the market.
- Rise in Home-Based Therapies – The shift towards at-home patient care is accelerating the adoption of autoinjectors as a preferred solution for self-administration of treatments.
Market Consolidation and Key Players
The autoinjector market remains highly consolidated, with leading companies continuously innovating to capture the majority of the market. Key players include:
- SHL Medical AG (Switzerland) – Known for its diverse range of autoinjector products, SHL Medical is focusing on the launch of technologically advanced devices to maintain its dominant market share.
- Ypsomed AG (Switzerland) – With a strong geographic presence and strategic partnerships, including a recent agreement with Novo Nordisk, Ypsomed is driving significant market influence.
- Becton, Dickinson and Company (BD) (US) – BD leverages its extensive distribution network and innovative drug delivery systems to strengthen its market position globally.
- Recipharm AB (Sweden), West Pharmaceutical Services, Inc. (US), and Phillips-Medisize (US) are also key players contributing to market growth.
Strategic Moves and Future Outlook
Companies like SHL Medical are ramping up production capacities to meet growing demand, while Ypsomed is expanding its footprint through strategic partnerships and alliances. For instance, the Ypsomed-Novo Nordisk partnership exemplifies the increasing trend of collaborations in the sector, aiming for long-term supply agreements of autoinjectors.
With increasing adoption of autoinjectors for chronic conditions, biologic therapies, and other at-home treatments, the market’s trajectory is set for significant growth.
Conclusion
As the autoinjector devices market continues to expand, companies that innovate and maintain strong market partnerships will thrive. For B2B leaders in the pharmaceutical and healthcare industries, this presents a critical opportunity for collaboration and growth.
